These findings establish Grx2 as a novel redox checkpoint controlling ABC-driven autoimmunity and propose therapeutic targeting of the Grx2-ROS axis in SLE and related chronic inflammation based resistant diseases. The gene discussed is GLRX2; the disease is systemic lupus erythematosus.